Percutaneous endoscopic gastrostomy prior to esophagectomy for esophageal cancer – a systematic review and meta-analysis. (1st February 2022)

• Record Type: Journal Article
• Authors: Fang, Hua-Chen; Farah, Musa Hassan; Shiue, Sheng-Jie; Cheng, Sheng-Wei; Shiue, Han-Shiang; Cheng, Chao-Ling; Chan, Tze-Sian; Liao, Ai-Ho; Wu, Ming-Shun
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 16:Number 2(2022)
• Page Start: 155
• Page End: 162
• Publication Date: 2022-02-01
• Subjects: Percutaneous endoscopic gastrostomy -- esophagus cancer -- neoadjuvant therapy -- systematic review and meta-analysis; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2022.2027754
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Background: For resectable esophageal cancer (EC), it remains controversial whether to place percutaneous endoscopic gastrostomy (PEG) before the curative surgery to provide nutritional support during the neoadjuvant therapy. Objective: To compare surgical outcomes for patients who received preoperative PEG and those without PEG placement (No-PEG) insertion prior to surgery in a potentially operable EC. Methods: A comprehensive literature search was conducted to identify randomized and non-randomized studies comparing PEG and No-PEG groups. Results: Four retrospective studies with a total number of 1, 027 patients were identified and included in this meta-analysis. The differences in anastomotic leakage, anastomotic stricture, morbidity, pulmonary complications, wound infection, and hospital stay were not statistically significant between the two groups. Operation time was significantly shorter in the PEG group. There was no PEG-related gastric conduit failure and no leak from the PEG site in the PEG group. Conclusion: We conclude preoperative PEG for resectable EC is a safe procedure with no adverse effect on the gastric tube construction and anastomosis, it can be selectively inserted for EC patients with marked weight loss and malnutrition or those at risk of developing malnutrition during neoadjuvant therapy.